NCT03098589View on ClinicalTrials.gov

Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)

CompletedOBSERVATIONAL

Enrollment

1,149

Participants

Timeline

Start Date

May 30, 2017

Primary Completion Date

September 18, 2020

Study Completion Date

September 18, 2020

Conditions

Lymphoma

Interventions

DRUG

Revlimid

Revlimid

Trial Locations (1)

820-8505

ASO KK Iizuka Hospital, Iizuka

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Celgene

INDUSTRY